Trinity Biotech About
Trinity Trinity Biotech plc develops, manufactures
and markets diagnostic test kits used
for the clinical laboratory and point-of-care
segments of the diagnostic market. These
test kits are used to detect infectious
diseases, sexually transmitted diseases,
blood coagulation disorders and autoimmune
disorders. The Company markets over 500
different diagnostic products in 80 countries.
Trinity Biotech's product areas can be
broken down under the headings of the
six key technologies: Enzyme Immunoassays,
Haemostasis, Fluorescence Assays, Rapid
Assays, Western Blot Assays and Clinical
Chemistry. trib Combretastatin -- Combretastatin represents
a new class of therapeutic compounds known
as vascular targeting agents. These agents
may be useful in disease conditions or
pathologies such as cancer, where an abnormal
growth of blood vessels is an essential
component to the disease and its progression.
Combretastatin has shown the ability in
both preclinical animal model and clinical
trials to drastically reduce blood flow
in tumors. CA4P -- Anaplastic Thyroid Cancer; Imageable
Tumors Trinity Biotech plc is a public company
(NASDAQ: TRIB) with manufacturing facilities
in Bray, Ireland, Jamestown, New York
and Carlsbad, California. The company
specialises in the development, manufacture
and marketing of diagnostic products which
utilise immunoassay technologies. Trinity
markets over 120 products through distributors
in 80 countries. The company was formed
in 1992 and attained its first full year
of profit in 1997. Trinity Biotech has
expanded through a combination of internal
and acquisition-led growth. Trinity's
major developments are as follows: More
on Trinity Biotech Key
Statistics for Trinity Biotech
Basic
Chart for Trinity Biotech